Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 6/20 | 0.52 |
| ▸ | FEN1 | P39748 | 6/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 6/20 | 0.51 |
| ▸ | TEK | Q02763 | 4/20 | 0.51 |
| ▸ | KDR | P35968 | 6/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13219902 | 0.92 | KDR (0.54) | ALOX5APFEN1KITCSF1RLCK | |
| SCHEMBL5491872 | 0.87 | LCK (0.64) | KITLCKTEKKDRMAPK14 | |
| SCHEMBL2962002 | 0.82 | LCK (0.63) | KITCSF1RLCKTEKKDR | |
| SCHEMBL13220045 | 0.82 | TRPV1 (0.56) | KITCSF1RLCKTEKKDR | |
| SCHEMBL2962918 | 0.81 | TEK (0.73) | KITCSF1RLCKTEKKDR | |
| SCHEMBL13220010 | 0.80 | LCK (0.53) | ALOX5APFEN1KITCSF1RLCK | |
| SCHEMBL5492387 | 0.80 | LCK (0.74) | LCKTEKKDRMAPK14BTK | |
| SCHEMBL13219893 | 0.79 | MAPT (0.55) | KITCSF1RLCKTEKKDR | |
| SCHEMBL22025009 | 0.79 | PTGS1 (0.54) | KITCSF1RTMPRSS4 | |
| SCHEMBL13220040 | 0.78 | LCK (0.71) | KITCSF1RLCKTEKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776869-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | IRAK3, IRAK1, MAP3K1 | ALOX5AP 755/4885FEN1 1640/4885KIT 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.